Design: This phase I dose-ranging study of 2 weeks of twice-daily dextrin sulphate (DS), a sulphated polymer with in vitro activity against HIV, was designed in 2 parts. Part A was a randomized, placebo-controlled, double-blind, 3-arm trial (DS4%, DS1%, placebo) in HIV-negative women. In part B, HIV-positive women received DS4% and HIV-negative women were randomized to DS4% or no gel.
THE HIV PANDEMIC CONTINUES with an estimated 5 million new infections in 2003, the majority of which were acquired through heterosexual intercourse. 1 New female-controlled methods such as microbicides are urgently needed so that women can take the initiative in protecting themselves from HIV/AIDS and other sexually transmitted infections. 2 Mathematical modeling suggests that microbicides with even moderate efficacy could have a major impact on HIV transmission, e.g., a 60% efficacious product, available to 20% of women and used in 50% of sex acts when a condom is not used could prevent 2.5 million new HIV infections over 3 years in high-incidence countries. 3 Nonoxynol-9 was not effective in preventing HIV, 4 but the experience gained in evaluating this product has assisted in determining the appropriate assessments for novel products, as well as providing a positive control for laboratory and animal testing. Important lessons learned were the need to demonstrate an absence of vaginal irritation during safety trials and a lack of interference with the local immune defense system in preclinical evaluations. 5, 6 The microbicide dextrin sulphate (DS) gel is being investigated as a candidate for phase III trials. 7, 8 Other microbicides in or soon to begin this phase are: Buffergel, Carraguard, cellulose sulfate, PRO2000, and Savvy. DS is a polyanion and blocks the entry of HIV at the surface of the cell. 9 It has anticoagulant activity, 10 but systemic absorption is unlikely because of its high molecular weight. The gel can be manufactured relatively cheaply, is highly stable, compatible with latex condoms, and nonspermicidal. Three phase I clinical trials of DS gel have been completed involving 127 healthy female volunteers who received up to 0.125% DS or matched placebo. 11, 12 These studies showed that DS at a concentration of 0.125% was safe and well tolerated. At that time, macaque challenge experiments also suggested a dose-dependent protective effect, and it was therefore decided to investigate higher doses of DS. 13 The aim of the current study was to identify the highest tolerable concentration of DS to be explored in 2 populations: a low-risk cohort in Uganda and a high-risk cohort in Côte d'Ivoire. To achieve this, the safety and acceptability of 2 concentrations of DS gel (1% and 4%) compared with matched placebo were explored over a 14-day exposure period in sexually active HIV-negative women in part A before exposing HIV-positive women to the highest tolerable dose in part B.
Methods
This trial was conducted at the Clinical Trials Centre, St Mary's Hospital, London, and the Institute of Tropical Medicine, Antwerp, between April and December 2000 and was approved by the ethics committee of each center. The study was designed in 2 parts with participants randomized in a double-blind manner to receive DS4%, DS1%, or placebo gel in a ratio 2:2:1 in part A to identify the highest tolerable dose in HIV-negative women. In part B, 10 HIV-positive and 10 HIV-negative women were to have been allocated to DS4%, but on the recommendation of the Data Monitoring Committee, the number of HIV-positive women on DS4% was increased to 20, and 20 HIV-negative women were randomly allocated to DS4% or no gel in equal numbers.
The DS gel consisted of 40 mg/mL and 10 mg/mL DS (4%, total dose 80 mg; 1%, total dose 20 mg, respectively) in a vehicle composed of 500 g/mL lactic acid, 10,000 g/g carbopol 974-P, sodium hydroxide (for pH adjustment to 4.5), and purified water. The placebo gel consisted of the vehicle alone.
There were 4 scheduled study visits: screening, enrollment, follow up (after 14 days use of study gel), and final (7 days after discontinuing use of the study gel). Informed consent was gained both at screening and again at enrollment. At screening, HIVnegative women received pretest counseling and an HIV test; HIV-positive women had a CD4 count and viral load measurement. At enrollment, those whose screening results met the entry criteria, or who had completed treatment for any sexually transmitted infections (STIs) diagnosed at screening, were enrolled in the study. Volunteers were asked to insert 2 mL of the allocated gel twice daily with a supplementary dose before sexual intercourse if the last dose of gel had been applied more than 1 hour previously. A maximum of 3 doses of study gel could be applied in any 24-hour period. Participants were provided with spermicide-free male latex condoms. Participants were asked to record gel use, coital frequency, and genital symptoms on a diary card. At the follow-up visit, participants were questioned about symptoms and product acceptability, and they returned used applicators and unused gel.
Hematologic (full blood count, differential, and platelets) and biochemical (liver function tests, creatinine, urea, and electrolytes) laboratory safety studies, including activated partial thromboplastin time (APTT) and thrombin time (TT), were performed at screening, follow up, and at the final visit.
A colposcopy was performed at each study visit according to the modified World Health Organization guidelines 14 to detect macroscopic evidence of mucosal changes. A standardized diagram was developed to record all findings. Lavage specimens were collected after irrigation of the vaginal walls and fornices. Vaginal biopsies were collected from the outer lateral aspect of the ectocervix only at the U.K. site. The left side was sampled at screening and the right at follow up, and was not directed by the presence of erythema.
The following STI tests were performed at screening and follow up: Chlamydia trachomatis (CT) using ligase chain reaction (LCR) or polymerase chain reaction (PCR); Neisseria gonorrhoeae (NG) by culture or PCR; wet mount for Trichomonas vaginalis; Candida albicans by culture; and identification of clue cells on microscopy for bacterial vaginosis (BV). Enzyme-linked immunosorbent assay syphilis serology was performed at screening in a double-blind manner to receive vaginal DS 4%. 
Results

Study Population
Fifty-five women were screened for part A at 2 centers (27 London, 28 Antwerp) of whom 5 were not enrolled ( Fig. 1 ). Fifty-six women (31 HIV-negative, 25 HIV-positive) were screened for part B, and 6 of these were not enrolled (Fig. 2) . Fourteen HIV-positive participants were enrolled in Antwerp and 6 in London, with equal numbers of HIV-negative women at both centers. All participants completed the study schedule in parts A and B.
The results for the women enrolled in both parts are presented together, with the data on DS4% in HIV-negative participants in part A and part B combined. Data from the 100 women were used for the baseline and acceptability analyses. Ninety-nine women were included in the follow-up analysis, including the colposcopy data; one was excluded at the follow-up visit as a result of noncompliance with visit timing, follow-up examination, and gel use.
Baseline characteristics of the study groups are shown in Table  1 . The HIV-infected women were slightly older, more likely to be nonwhite, less likely to be taking hormones, and more likely to report a history of sexually transmitted infection.
Sexual Activity and Gel Use
Seventy-three (73%) of all participants had sex more than 4 times during the gel period. Medians and ranges are provided in Table 2 . Fifty-nine of 80 (74%) women allocated to gel applied it 27 times or more. All but one reported that they found the gel easy to use.
Adverse Events
Fifteen (15%) participants had abnormalities in one or more of their routine laboratory parameters at baseline, with the highest frequency (30%) in the HIV-positive group and the lowest (3%) in the HIV-negative DS4% group. Twenty-five had an abnormality at follow up only and distribution across the groups was as follows: 6 no gel (30%), 3 placebo (30%), 3 DS1% (15%), 7 HIV-negative DS4% (23%), and 6 HIV-positive DS4% (30%). There was only one severe abnormality in coagulation parameters, an elevated APTT ration of 2.7 (upper limit of normal 1.2), and this occurred at a follow-up visit in a participant allocated to placebo gel but was not confirmed on repeat testing. Table 3 summarizes the colposcopic findings in enrolled participants at baseline and new findings at follow up by group and HIV status. Twelve women had mild local or diffuse erythema or petechiae at one or both of the baseline colposcopies, which was Vol. 32 • No. 12 767 PHASE I MICROBICIDE STUDY OF DEXTRIN SULPHATE observed again at one or both of the follow-up colposcopies without an increase in severity. These 12 are not included in the follow-up findings in the table. Two women had small superficial disruptions of the vulval epithelia at baseline (visits 1 and 2): in one woman a single laceration and in the other a lesion of the perineum was present. One HIV-positive woman had 4 pinhead punctiform superficial lesions on the cervicovaginal epithelium at baseline. One woman (no gel) had cervicovaginal edema at baseline; no cause was found and this was not observed at follow up. Fifteen women had mild cervicovaginal erythema and one had mild vulval erythema. Only one of these 16 women had Candida. At follow up, no new cases of disruption of the epithelia were detected. Fifteen new cases of cervicovaginal erythema were seen, all of which were mild except one (DS4%). One of these 15 participants also had mild vulval erythema; the 16th woman had mild vulval erythema alone. One third of women that had erythema at a follow-up visit were positive for Candida.
Biopsy results of U.K. participants showed inflammation of epithelia and/or lamina propria in 12 women at baseline and 8 at follow up. Of these 8 results, only 4 were new events. The changes were considered mild in 2 of the 4 cases (one no gel, one HIVnegative DS4%) and moderate (one no gel, one HIV-negative DS4%) in the other 2.
Twenty-seven participants reported a total of 38 symptoms of genital discomfort at follow up with itching the most common (14 of 38). The majority (68%) of these symptoms was mild, but 6 participants considered their symptoms to be moderate in severity, 2 of whom were on DS4% (HIV-negative) and one in each of the other groups, including DS4% (HIV-positive). One woman (DS4%, HIV-negative) experienced severe dysuria as a result of a urinary tract infection. There were no differences between the groups, and the highest frequency of participants reporting symptoms, 30%, was recorded in the no-gel and placebo groups.
In total, 24 women experienced 31 episodes of intermenstrual bleeding (IMB) during the study period ( Table 4 ). The frequency of IMB was significantly higher in those exposed to any gel (23 of 80) when compared with no gel (one of 20), with the highest frequency occurring in the placebo group (4 of 10) (Fisher exact test P ϭ 0.037). In all but one of the episodes, the bleeding or spotting was considered mild. One episode (placebo), which occurred in a woman with an intrauterine contraceptive device and a history of IMB, was considered moderate with fresh blood loss lasting for 5 days. Three gave histories that linked the bleeding to the applicator, another 3 occurred after sex, and one was possibly a result of a participant stopping her pill in the previous cycle. There was no 4 (20) 1 (10) 4 (20) 3 (10) 1 (5) Candida (%)
2 (10) 2 (20) 3 (15) 4 (13) 5 (25) DS indicates dextrin sulphate. suggestion of an association among ectopy, smoking, oral hormonal contraception, and IMB in the study population overall.
Sexually Transmitted Infection and Vaginal Infections
There were no new STIs diagnosed during the course of the study. Candida was more common at baseline then at follow up, and there were no new episodes of bacterial vaginosis during follow up.
Discussion
Findings from the clinical interview, vaginal examination, and laboratory tests indicate that 14-day twice-daily administration of vaginal DS4% gel was well tolerated in that women continued on gel through to the final visit. There were no dose-dependent adverse events, no new epithelial disruptions while on the gel, and the coagulation parameters did not suggest that the gels were systemically absorbed.
The IMB observed was considered a mild adverse event in all but one woman and no participants discontinued gel. Nevertheless, the clinical investigators and the independent committees overseeing the trial were concerned about proceeding to a trial population with a higher prevalence of HIV without further exploration, because of the possibility that HIV transmission could be facilitated in some way. Evidence from serodiscordant couple studies in Europe and the United States suggests that sex during menses may be a risk factor for acquisition of HIV infection in men, although not in women. 15, 16 There were no published data on the prevalence of IMB or spotting in a general population, but 26% in part A over a 2-week period was considered higher than expected. In the largest previous DS safety study, 11 15% of participants experienced IMB. The inclusion of the no-gel control group in part B confirmed that IMB was more common in all gel groups compared with no gel. Overall, combining both parts of the study, there was no association with active product and no clinically relevant disturbance of the coagulation parameters to suggest this was a systemic effect of dextrin sulphate. Although the numbers were too small for valid comparisons, there was no suggestion that the IMB was associated with hormonal contraception, large ectopies, or a history of IMB.
One possible explanation was that accumulation of gel in the vagina could either facilitate bleeding in a nonspecific way or result in the recognition of blood loss that would otherwise have been absorbed and gone unnoticed. The investigators hypothesized that gel would be less likely to accumulate if used before sex only. The "follow-up" number does not include findings that persisted from baseline. *n ϭ 19 at follow-up because one participant in the DS1% group declined examination. DS indicates dextrin sulphate. To evaluate this, 20 new candidates were invited to follow the visit schedule and use gel presex only for 2 weeks. Six (30%) of these women reported IMB, 4 noting a single episode and 2 reporting blood in the discharge on more than one occasion, suggesting that this was an unlikely explanation. Another possibility was that the IMB was the result of the applicator, and to explore this further, women who had been on the no-gel group in part B were invited to return for a baseline visit (equivalent to visit 2), use an empty applicator twice a day for 2 weeks, and then attend for the follow-up evaluations. Fifteen of the 20 women participated, and of these 2 reported IMB (13%) while using the empty applicator. Neither had experienced this during or subsequent to completing part B. One of these women had noted a small amount of blood on the applicator. This provided limited evidence that the applicator, or method of application, may be the explanation. Finally, the possibility that the IMB was the result of the vehicle, which contained lactic acid, Carbopol 974-P, and sodium hydroxide, cannot be excluded.
In conclusion, this trial provides further evidence for the safety and acceptability of dextrin sulphate vaginal gel in these populations and the first clinical evidence of the safety of DS4%. Because of the IMB, the investigators from Côte d'Ivoire decided against starting the expanded safety study in a population of sex workers. It was therefore agreed to proceed with DS4% in the expanded safety study in Uganda, but to restrict entry initially to 35 low-risk HIV-negative women, to amend the design to include a no-gel group, and to monitor bleeding events closely.
